These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
61 related articles for article (PubMed ID: 22057972)
21. Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Corbetta S; Vaira V; Guarnieri V; Scillitani A; Eller-Vainicher C; Ferrero S; Vicentini L; Chiodini I; Bisceglia M; Beck-Peccoz P; Bosari S; Spada A Endocr Relat Cancer; 2010 Mar; 17(1):135-46. PubMed ID: 19926710 [TBL] [Abstract][Full Text] [Related]
22. Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles. Fulci V; Colombo T; Chiaretti S; Messina M; Citarella F; Tavolaro S; Guarini A; Foà R; Macino G Genes Chromosomes Cancer; 2009 Dec; 48(12):1069-82. PubMed ID: 19760605 [TBL] [Abstract][Full Text] [Related]
23. Bilateral breast cancer. Gogas J; Markopoulos C; Skandalakis P; Gogas H Am Surg; 1993 Nov; 59(11):733-5. PubMed ID: 8239195 [TBL] [Abstract][Full Text] [Related]
24. [The prognosis of bilateral breast carcinoma compared to unilateral breast tumor. 5- and 10-year follow-ups]. Mose S; Adamietz IA; Thilmann C; Saran F; Pahnke R; Böttcher HD Strahlenther Onkol; 1995 Apr; 171(4):207-13. PubMed ID: 7740408 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of MiR-21 and MiR-10b Expression of Human Breast Cancer in West Sumatera. Yanwirasti ; A Harahap W; Arisanty D Pak J Biol Sci; 2017; 20(4):189-196. PubMed ID: 29023075 [TBL] [Abstract][Full Text] [Related]
26. TP53 mutations in synchronous and metachronous bilateral breast carcinomas. Suspitsin EN; Due EU; Vu P; Hirvonen A; Børresen-Dale AL; Imyanitov EN Cancer Genet Cytogenet; 2008 Jul; 184(2):119-21. PubMed ID: 18617062 [No Abstract] [Full Text] [Related]
27. Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Patel JB; Appaiah HN; Burnett RM; Bhat-Nakshatri P; Wang G; Mehta R; Badve S; Thomson MJ; Hammond S; Steeg P; Liu Y; Nakshatri H Oncogene; 2011 Mar; 30(11):1290-301. PubMed ID: 21057539 [TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of microRNA-10b overexpression in breast cancer: a meta-analysis. Wang N; Chen P; Huang LP; Wang TZ Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173192 [TBL] [Abstract][Full Text] [Related]
29. Systemic investigations into the molecular features of bilateral breast cancer for diagnostic purposes. Imyanitov EN; Kuligina ES Expert Rev Mol Diagn; 2020 Jan; 20(1):41-47. PubMed ID: 31835926 [No Abstract] [Full Text] [Related]
30. Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients. Khalighfard S; Alizadeh AM; Irani S; Omranipour R Sci Rep; 2018 Dec; 8(1):17981. PubMed ID: 30568292 [TBL] [Abstract][Full Text] [Related]
31. Hyperthermia-driven aberrations of secreted microRNAs in breast cancer in vitro. Erbes T; Hirschfeld M; Waldeck S; Rücker G; Jäger M; Willmann L; Kammerer B; Mayer S; Gitsch G; Stickeler E Int J Hyperthermia; 2016 Sep; 32(6):630-42. PubMed ID: 27380148 [TBL] [Abstract][Full Text] [Related]
32. The molecular and clinicopathologic characteristics of bilateral breast cancer. Chen SF; Du CW; Yang P; Zhang HW; Kwan M; Zhang GJ Sci Rep; 2013; 3():2590. PubMed ID: 24005135 [TBL] [Abstract][Full Text] [Related]
33. A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer. Meyniel JP; Cottu PH; Decraene C; Stern MH; Couturier J; Lebigot I; Nicolas A; Weber N; Fourchotte V; Alran S; Rapinat A; Gentien D; Roman-Roman S; Mignot L; Sastre-Garau X BMC Cancer; 2010 May; 10():222. PubMed ID: 20492709 [TBL] [Abstract][Full Text] [Related]
34. Dissecting Time- from Tumor-Related Gene Expression Variability in Bilateral Breast Cancer. Callari M; Dugo M; Miodini P; Veneroni S; Bianchini G; Daidone MG; Cappelletti V Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29315233 [TBL] [Abstract][Full Text] [Related]
35. Correction: Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer. Cancer Res; 2016 Sep; 76(17):5186. PubMed ID: 27587652 [No Abstract] [Full Text] [Related]
36. Prognostic and Clinicopathological Significance of MiR-155 in Breast Cancer: A Systematic Review. Grimaldi AM; Nuzzo S; Condorelli G; Salvatore M; Incoronato M Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823863 [TBL] [Abstract][Full Text] [Related]
37. Associations Between miRNAs and Two Different Cancers: Breast and Colon. Kundaktepe BP; Sozer V; Papila C; Durmus S; Kocael PC; Simsek G; Gelisgen R; Zengin K; Ulualp K; Uzun H Cancer Manag Res; 2020; 12():871-879. PubMed ID: 32104069 [TBL] [Abstract][Full Text] [Related]
38. The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta-analysis of studies from recent decade (2008-2018). Pan B; Xu Y; Zhou YD; Yao R; Wu HW; Zhu QL; Wang CJ; Mao F; Lin Y; Shen SJ; Sun Q Cancer Med; 2019 Jun; 8(6):2908-2918. PubMed ID: 31038845 [TBL] [Abstract][Full Text] [Related]
39. MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities. Chen SN; Chang R; Lin LT; Chern CU; Tsai HW; Wen ZH; Li YH; Li CJ; Tsui KH Int J Environ Res Public Health; 2019 Apr; 16(9):. PubMed ID: 31035447 [TBL] [Abstract][Full Text] [Related]